Mill Capital Management LLC Takes $522,000 Position in Becton, Dickinson and Company $BDX

Mill Capital Management LLC acquired a new position in Becton, Dickinson and Company (NYSE:BDX) during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund acquired 3,449 shares of the medical instruments supplier’s stock, valued at approximately $522,000.

Other institutional investors also recently bought and sold shares of the company. Brighton Jones LLC grew its holdings in Becton, Dickinson and Company by 98.2% in the 4th quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier’s stock worth $401,000 after acquiring an additional 877 shares during the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. raised its stake in shares of Becton, Dickinson and Company by 4.4% during the fourth quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 627,900 shares of the medical instruments supplier’s stock valued at $122,403,000 after acquiring an additional 26,671 shares during the last quarter. Cooke & Bieler LP boosted its holdings in shares of Becton, Dickinson and Company by 27.2% during the fourth quarter. Cooke & Bieler LP now owns 1,126,471 shares of the medical instruments supplier’s stock worth $218,614,000 after purchasing an additional 240,673 shares during the period. KLP Kapitalforvaltning AS boosted its holdings in shares of Becton, Dickinson and Company by 61.2% during the fourth quarter. KLP Kapitalforvaltning AS now owns 172,580 shares of the medical instruments supplier’s stock worth $33,493,000 after purchasing an additional 65,500 shares during the period. Finally, Northside Capital Management LLC grew its stake in shares of Becton, Dickinson and Company by 18.3% in the second quarter. Northside Capital Management LLC now owns 61,324 shares of the medical instruments supplier’s stock worth $9,280,000 after purchasing an additional 9,494 shares during the last quarter. 86.97% of the stock is currently owned by hedge funds and other institutional investors.

Becton, Dickinson and Company Stock Performance

Shares of Becton, Dickinson and Company stock opened at $183.16 on Friday. Becton, Dickinson and Company has a 12 month low of $127.59 and a 12 month high of $187.35. The firm has a market capitalization of $50.47 billion, a P/E ratio of 55.17, a P/E/G ratio of 12.82 and a beta of 0.19. The company has a current ratio of 0.87, a quick ratio of 0.51 and a debt-to-equity ratio of 0.55. The business has a fifty day simple moving average of $157.84 and a two-hundred day simple moving average of $161.70.

Becton, Dickinson and Company (NYSE:BDX) last released its earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 earnings per share for the quarter, topping analysts’ consensus estimates of $3.14 by $0.09. The firm had revenue of $4.98 billion for the quarter, compared to the consensus estimate of $4.89 billion. Becton, Dickinson and Company had a net margin of 4.52% and a return on equity of 14.79%. The company’s revenue was up 5.4% compared to the same quarter last year. During the same period in the prior year, the firm earned $3.68 EPS. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. On average, equities analysts forecast that Becton, Dickinson and Company will post 12.67 earnings per share for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 30th. Shareholders of record on Wednesday, September 9th will be issued a $1.05 dividend. This represents a $4.20 dividend on an annualized basis and a yield of 2.3%. The ex-dividend date is Wednesday, September 9th. Becton, Dickinson and Company’s dividend payout ratio is 126.51%.

Insider Buying and Selling at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, CEO Thomas E. Polen, Jr. sold 4,152 shares of the firm’s stock in a transaction that occurred on Thursday, August 13th. The shares were sold at an average price of $185.00, for a total transaction of $768,120.00. Following the completion of the transaction, the chief executive officer owned 110,163 shares of the company’s stock, valued at approximately $20,380,155. This trade represents a 3.63% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael David Garrison sold 1,100 shares of Becton, Dickinson and Company stock in a transaction that occurred on Wednesday, June 24th. The shares were sold at an average price of $145.66, for a total transaction of $160,226.00. Following the transaction, the executive vice president owned 13,172 shares of the company’s stock, valued at $1,918,633.52. The trade was a 7.71% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 11,779 shares of company stock valued at $1,974,669. Corporate insiders own 0.40% of the company’s stock.

Analyst Ratings Changes

A number of research analysts recently issued reports on the company. Bank of America reduced their price target on Becton, Dickinson and Company from $177.00 to $170.00 in a report on Friday, June 12th. Evercore set a $180.00 price objective on Becton, Dickinson and Company in a report on Monday, July 6th. TD Cowen lifted their price objective on Becton, Dickinson and Company from $163.00 to $182.00 and gave the stock a “hold” rating in a research report on Wednesday, August 5th. Royal Bank Of Canada boosted their target price on Becton, Dickinson and Company from $180.00 to $190.00 and gave the company a “sector perform” rating in a research note on Thursday. Finally, Wells Fargo & Company upped their target price on Becton, Dickinson and Company from $161.00 to $170.00 and gave the company an “equal weight” rating in a report on Friday, August 7th. Eight investment analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Becton, Dickinson and Company has an average rating of “Hold” and an average target price of $185.67.

About Becton, Dickinson and Company

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.